FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137487944> ?p ?o ?g. }

• W2137487944 endingPage "61" @default.
• W2137487944 startingPage "56" @default.
• W2137487944 abstract "Background/AimsOphthalmologic side effects have been reported during interferon therapy, particularly retinal lesions and neurovisual impairment. The aim of this prospective study was to assess the nature and the frequency of such lesions during alpha-interferon therapy for viral hepatitis.MethodsBetween 1995 and 2003, 156 patients treated with standard or pegylated alpha-interferon, with or without ribavirin, had a regular ophthalmologic examination before and during treatment. No patient had signs of retinopathy before treatment. Cotton-wool spots were found in 31 patients and retinal hemorrhage in nine patients during treatment (24% of patients). These lesions remained asymptomatic and disappeared in all patients. A previous history of arterial hypertension (RR 4.60, 95% CI 1.95–10.85), age above 45 years (RR 2.80, 95% CI 1.36–5.85), and use of pegylated alpha-interferon (RR 2.75, 95% CI 1.41–5.38) were significantly associated with retinopathy. Neurovisual impairment was present in 31 patients (20%) before treatment and in 74 patients (47%) during treatment.ConclusionsIn conclusion, this study showed that signs of retinopathy and neurovisual impairment were common in patients receiving alpha-interferon therapy but were rarely symptomatic. It suggests that alpha-interferon may usually be continued in asymptomatic patients as long as there is careful fundoscopic examination. Ophthalmologic side effects have been reported during interferon therapy, particularly retinal lesions and neurovisual impairment. The aim of this prospective study was to assess the nature and the frequency of such lesions during alpha-interferon therapy for viral hepatitis. Between 1995 and 2003, 156 patients treated with standard or pegylated alpha-interferon, with or without ribavirin, had a regular ophthalmologic examination before and during treatment. No patient had signs of retinopathy before treatment. Cotton-wool spots were found in 31 patients and retinal hemorrhage in nine patients during treatment (24% of patients). These lesions remained asymptomatic and disappeared in all patients. A previous history of arterial hypertension (RR 4.60, 95% CI 1.95–10.85), age above 45 years (RR 2.80, 95% CI 1.36–5.85), and use of pegylated alpha-interferon (RR 2.75, 95% CI 1.41–5.38) were significantly associated with retinopathy. Neurovisual impairment was present in 31 patients (20%) before treatment and in 74 patients (47%) during treatment. In conclusion, this study showed that signs of retinopathy and neurovisual impairment were common in patients receiving alpha-interferon therapy but were rarely symptomatic. It suggests that alpha-interferon may usually be continued in asymptomatic patients as long as there is careful fundoscopic examination." @default.
• W2137487944 created "2016-06-24" @default.
• W2137487944 creator A5004064806 @default.
• W2137487944 creator A5046804809 @default.
• W2137487944 creator A5047225198 @default.
• W2137487944 creator A5060300612 @default.
• W2137487944 creator A5061596981 @default.
• W2137487944 date "2006-01-01" @default.
• W2137487944 modified "2023-10-04" @default.
• W2137487944 title "Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis" @default.
• W2137487944 cites W124566017 @default.
• W2137487944 cites W1968568326 @default.
• W2137487944 cites W1972862906 @default.
• W2137487944 cites W1972965443 @default.
• W2137487944 cites W1979562675 @default.
• W2137487944 cites W1997461520 @default.
• W2137487944 cites W1998424597 @default.
• W2137487944 cites W2020347377 @default.
• W2137487944 cites W2028403928 @default.
• W2137487944 cites W2060024172 @default.
• W2137487944 cites W2061303970 @default.
• W2137487944 cites W2068908510 @default.
• W2137487944 cites W2070763663 @default.
• W2137487944 cites W2085925469 @default.
• W2137487944 cites W2100911110 @default.
• W2137487944 cites W2136025187 @default.
• W2137487944 cites W2150886867 @default.
• W2137487944 cites W2466165747 @default.
• W2137487944 cites W2571723958 @default.
• W2137487944 cites W2024646055 @default.
• W2137487944 doi "https://doi.org/10.1016/j.jhep.2005.07.026" @default.
• W2137487944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16223542" @default.
• W2137487944 hasPublicationYear "2006" @default.
• W2137487944 type Work @default.
• W2137487944 sameAs 2137487944 @default.
• W2137487944 citedByCount "59" @default.
• W2137487944 countsByYear W21374879442012 @default.
• W2137487944 countsByYear W21374879442013 @default.
• W2137487944 countsByYear W21374879442014 @default.
• W2137487944 countsByYear W21374879442015 @default.
• W2137487944 countsByYear W21374879442016 @default.
• W2137487944 countsByYear W21374879442017 @default.
• W2137487944 countsByYear W21374879442019 @default.
• W2137487944 countsByYear W21374879442020 @default.
• W2137487944 countsByYear W21374879442021 @default.
• W2137487944 countsByYear W21374879442022 @default.
• W2137487944 crossrefType "journal-article" @default.
• W2137487944 hasAuthorship W2137487944A5004064806 @default.
• W2137487944 hasAuthorship W2137487944A5046804809 @default.
• W2137487944 hasAuthorship W2137487944A5047225198 @default.
• W2137487944 hasAuthorship W2137487944A5060300612 @default.
• W2137487944 hasAuthorship W2137487944A5061596981 @default.
• W2137487944 hasBestOaLocation W21374879441 @default.
• W2137487944 hasConcept C126322002 @default.
• W2137487944 hasConcept C134018914 @default.
• W2137487944 hasConcept C141071460 @default.
• W2137487944 hasConcept C188816634 @default.
• W2137487944 hasConcept C197934379 @default.
• W2137487944 hasConcept C199360897 @default.
• W2137487944 hasConcept C203014093 @default.
• W2137487944 hasConcept C2522874641 @default.
• W2137487944 hasConcept C2776178377 @default.
• W2137487944 hasConcept C2776408679 @default.
• W2137487944 hasConcept C2776455275 @default.
• W2137487944 hasConcept C2776461080 @default.
• W2137487944 hasConcept C2776689232 @default.
• W2137487944 hasConcept C2777910003 @default.
• W2137487944 hasConcept C2778313320 @default.
• W2137487944 hasConcept C2780040827 @default.
• W2137487944 hasConcept C2780149145 @default.
• W2137487944 hasConcept C2909179924 @default.
• W2137487944 hasConcept C3454156 @default.
• W2137487944 hasConcept C41008148 @default.
• W2137487944 hasConcept C555293320 @default.
• W2137487944 hasConcept C71924100 @default.
• W2137487944 hasConcept C90924648 @default.
• W2137487944 hasConceptScore W2137487944C126322002 @default.
• W2137487944 hasConceptScore W2137487944C134018914 @default.
• W2137487944 hasConceptScore W2137487944C141071460 @default.
• W2137487944 hasConceptScore W2137487944C188816634 @default.
• W2137487944 hasConceptScore W2137487944C197934379 @default.
• W2137487944 hasConceptScore W2137487944C199360897 @default.
• W2137487944 hasConceptScore W2137487944C203014093 @default.
• W2137487944 hasConceptScore W2137487944C2522874641 @default.
• W2137487944 hasConceptScore W2137487944C2776178377 @default.
• W2137487944 hasConceptScore W2137487944C2776408679 @default.
• W2137487944 hasConceptScore W2137487944C2776455275 @default.
• W2137487944 hasConceptScore W2137487944C2776461080 @default.
• W2137487944 hasConceptScore W2137487944C2776689232 @default.
• W2137487944 hasConceptScore W2137487944C2777910003 @default.
• W2137487944 hasConceptScore W2137487944C2778313320 @default.
• W2137487944 hasConceptScore W2137487944C2780040827 @default.
• W2137487944 hasConceptScore W2137487944C2780149145 @default.
• W2137487944 hasConceptScore W2137487944C2909179924 @default.
• W2137487944 hasConceptScore W2137487944C3454156 @default.
• W2137487944 hasConceptScore W2137487944C41008148 @default.
• W2137487944 hasConceptScore W2137487944C555293320 @default.
• W2137487944 hasConceptScore W2137487944C71924100 @default.

• next